Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects

    June 2009 in “ Current drug metabolism ”
    Jörg T. Hartmann, Michael Haap, Hans‐Georg Kopp, Hans‐Peter Lipp
    Studysummary This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on eurekaselect.com →
    Discuss this study in the Community →